Fifth Scientific Kratom Symposium Draws 100 Researchers to UF; NIDA Director Urges More Clinical Trials

Why it matters

As state bans and federal scheduling debates multiply, the kratom research community is racing to generate the clinical data needed to inform policy—and this international gathering marks the most significant scientific convening on kratom to date. The NIDA director's call for urgency signals that federal research investment may increase.

The big picture

Kratom sits at the center of one of the most contested regulatory battles in American drug policy, with some states banning it outright while others regulate it under consumer protection frameworks. The scientific evidence base has lagged behind the policy debate, with very few human clinical trials completed. Events like this symposium aim to accelerate multidisciplinary research and communicate findings directly to regulators and policymakers.

Key findings

• Nora Volkow, MD, director of the National Institute on Drug Abuse (NIDA), delivered the keynote, calling for urgent clinical trials and public education on kratom risks
• About 100 scientists from roughly a dozen countries attended the four-day event, presenting nearly 50 papers on pre-clinical and clinical research, product quality, and regulatory science
• Lead researcher Dr. Christopher McCurdy called for regulation and education rather than prohibition, noting kratom's potential health benefits warrant continued study
• Presentations highlighted a key distinction between natural kratom leaf products and highly purified synthetic 7-OH derivatives, which carry much greater addiction risk
• New NIDA-funded studies from the University of Florida on kratom pharmacology, safety, and potential in opioid use disorder treatment were highlighted

What they say

"Regulation and education of kratom are key, not prohibition. There is still so much we don't know about the safety of kratom products, and from a scientific perspective, there could be real health benefits that are worth exploring." — Dr. Christopher McCurdy, UF College of Pharmacy

Bottom line

The NIDA director's rare personal appearance at a kratom symposium—and her call to accelerate clinical trials—signals that federal science agencies are taking kratom's dual risks and benefits seriously.